See more : MHP SE (MHPC.L) Income Statement Analysis – Financial Results
Complete financial analysis of GBS Inc. (GBS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GBS Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- CASIN Real Estate Development Group Co.,Ltd. (000838.SZ) Income Statement Analysis – Financial Results
- Bank of the Philippine Islands (BPHLF) Income Statement Analysis – Financial Results
- Texas Instruments Incorporated (0R2H.L) Income Statement Analysis – Financial Results
- StoneBridge Acquisition Corporation (APACW) Income Statement Analysis – Financial Results
- Shenzhen Overseas Chinese Town Co.,Ltd. (000069.SZ) Income Statement Analysis – Financial Results
GBS Inc. (GBS)
About GBS Inc.
GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 1.26M | 437.15K | 1.98M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 930.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 326.67K | 437.15K | 1.98M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 25.99% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 3.85M | 3.84M | 588.21K | 3.18M | 2.53M |
| General & Administrative | 0.00 | 4.92M | 3.72M | 2.43M | 3.55M | 2.08M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.03M | 4.92M | 3.72M | 2.43M | 3.55M | 2.08M |
| Other Expenses | 0.00 | -437.15K | -1.98M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.03M | 8.34M | 5.57M | 3.02M | 6.73M | 4.60M |
| Cost & Expenses | 8.96M | 8.34M | 5.57M | 2.83M | 6.73M | 4.60M |
| Interest Income | 9.68K | 14.43K | 13.81K | 97.00 | 188.00 | 564.00 |
| Interest Expense | -223.53K | 7.54K | 1.09M | 457.75K | 664.84K | 453.87K |
| Depreciation & Amortization | -966.73K | 38.36K | -370.20K | 150.96K | 57.88K | 36.96K |
| EBITDA | -13.56M | -8.30M | -5.94M | -2.68M | -6.67M | -4.57M |
| EBITDA Ratio | -1,079.03% | -1,898.34% | -300.11% | 0.00% | 0.00% | 0.00% |
| Operating Income | -12.60M | -8.34M | -5.57M | -2.83M | -6.73M | -4.60M |
| Operating Income Ratio | -1,002.11% | -1,907.11% | -281.42% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.96M | 2.90K | -1.49M | -335.96K | -664.65K | -453.31K |
| Income Before Tax | -10.63M | -8.33M | -7.06M | -3.16M | -7.39M | -5.06M |
| Income Before Tax Ratio | -845.89% | -1,906.45% | -356.49% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -38.36K | -22.92K | -29.17K | -57.69K | -36.39K |
| Net Income | -10.63M | -8.30M | -7.04M | -3.13M | -7.34M | -5.02M |
| Net Income Ratio | -845.89% | -1,897.68% | -355.33% | 0.00% | 0.00% | 0.00% |
| EPS | -10.58 | -0.57 | -0.52 | -0.28 | -0.65 | -0.44 |
| EPS Diluted | -10.58 | -0.57 | -0.52 | -0.28 | -0.65 | -0.44 |
| Weighted Avg Shares Out | 1.00M | 14.67M | 13.58M | 11.29M | 11.29M | 11.29M |
| Weighted Avg Shares Out (Dil) | 1.00M | 14.67M | 13.58M | 11.29M | 11.29M | 11.29M |
GBS (GBS) Stock: Why The Price Jumped Today
GBS Stock: The Covid Antibody Test News Shooting GBS Shares Higher Today
GBS Shares Are Rallying On Plans For COVID-19 Antibody Trials After Validation Study
GBS Inc. (GBS) CEO Steven Boyages on Q1 2022 Results - Earnings Call Transcript
FDA Pre-Submission for Saliva-Based Glucose Test to Replace Invasive Finger-Prick
GBS Inc. Announces its Pre-Submission package is with the FDA
GBS Inc. to Present at Upcoming September Virtual Investor Conferences
GBS Stock: Over 40% Increase Pre-Market Explanation
GBS Inc.: Can Its Technology Come Through?
GBS Inc. (GBS) CEO Harry Simeonidis on Q4 2021 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports